L. Gianni

Nature Reviews Clinical Oncology · 2002–2021

A researcher in the Science corpus: 17 papers; trusts 0 researchers and is trusted by 1 researcher here, as inferred from the citation graph.

Who trusts L. Gianni overall

  1. N. Almansour
  2. Carlos L. Arteaga
  3. N. Iqbal
  4. Hodgkin Lymphoma

Papers from L. Gianni's perspective

Ordered by how strongly the researchers L. Gianni trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Molecular portraits of human breast tumours (Nature)
  2. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer… (Journal of the National Cancer Institute)
  3. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. (Cancer Cell)
  4. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
  5. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. (Cancer Cell)
  6. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. (New England Journal of Medicine)
  7. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma (Modern Pathology)
  8. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. (Journal of Clinical Oncology)
  9. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. (Journal of Clinical Oncology)
  10. Mutational landscape and significance across 12 major cancer types (Nature)

Their papers